Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 1.00 |
| ▸ | HTR2B | P41595 | 19/20 | 1.00 |
| ▸ | HTR2A | P28223 | 18/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.77 |
| ▸ | MTOR | P42345 | 1/20 | 0.77 |
| ▸ | RAB9A | P51151 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sb-243213 SCHEMBL29697170 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL31060820 | 1.00 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL18321797 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-243213 SCHEMBL7473195 | 0.99 | HTR2C (0.98) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7078894 | 0.93 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7082914 | 0.90 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL7473325 | 0.88 | HTR2A (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| SCHEMBL2229787 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-242084 SCHEMBL29388888 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 | |
| Sb-242084 SCHEMBL29462298 | 0.87 | HTR2C (1.00) | HTR2CHTR2BHTR2ACYP2C9HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003011281-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER OR ATTENTION DEFICIT DISORDER | VERNALIS RESEARCH LIMITED (GB) | 2003-02-13 | — | — | WO | claimed |
| EP-0912554-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-11-27 | — | — | EP | claimed |
| US-6369060-B1 | CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY; 5-METHYL-6-TRIFLUOROMETHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY)-PYRIDIN-3-YL CARBAMOYL)INDOLINE AND 5-METHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY) -PYRIDAZIN-3-YLCARBAMOYL)-6-TRIFLUOROMETHYLINDOLINE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-09 | — | — | US | claimed |
| EP-0936924-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT 2C? ANTAGONIST AND A D 2? ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1999-08-25 | — | — | EP | claimed |
| EP-0912554-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | claimed |
| WO-1998004289-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT2C ANTAGONIST AND A D2 ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1998-02-05 | — | — | WO | claimed |
| WO-1997048699-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | claimed |
| EP-2651403-B1 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | GLAXO GROUP LTD (GB) | 2020-12-02 | — | — | EP | disclosed |
| WO-2016205631-A1 | SEROTONIN 2C RECEPTOR ANTAGONISTS TO PREVENT AND TREAT STRESS-RELATED TRAUMA DISORDERS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2016-12-22 | — | — | WO | disclosed |
| EP-2288345-B1 | PSYCHO-PHARMACEUTICALS | UNIV DUBLIN (IE) | 2015-06-10 | — | — | EP | disclosed |
| EP-2651403-A2 | USE OF LP-PLA2 INHIBITORS IN THE TREATMENT AND PREVENTION OF EYE DISEASES | Glaxo Group Limited (GB) | 2013-10-23 | — | — | EP | disclosed |
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | GLAXO GROUP LIMITED (GB) | 2013-10-10 | — | — | US | disclosed |
| EP-2108649-B1 | Novel indol carboxylic acid bispyridyl carboxamide derivatives as 5-HT2c receptor antagonists | KOREA RES INST CHEM TECH (KR) | 2013-04-24 | — | — | EP | disclosed |
| WO-2003011281-A1 | TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER OR ATTENTION DEFICIT DISORDER | VERNALIS RESEARCH LIMITED (GB) | 2003-02-13 | — | — | WO | disclosed |
| EP-0912554-B1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2002-11-27 | — | — | EP | disclosed |
| US-6369060-B1 | CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY; 5-METHYL-6-TRIFLUOROMETHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY)-PYRIDIN-3-YL CARBAMOYL)INDOLINE AND 5-METHYL-1-(6-(2-METHYLPYRIDIN-3-YLOXY) -PYRIDAZIN-3-YLCARBAMOYL)-6-TRIFLUOROMETHYLINDOLINE | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-04-09 | — | — | US | disclosed |
| EP-0936924-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT 2C? ANTAGONIST AND A D 2? ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1999-08-25 | — | — | EP | disclosed |
| EP-0912554-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1999-05-06 | — | — | EP | disclosed |
| WO-1998004289-A2 | PHARMACEUTICAL COMPOSITION CONTAINING A 5HT2C ANTAGONIST AND A D2 ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1998-02-05 | — | — | WO | disclosed |
| WO-1997048699-A1 | INDOLINE DERIVATIVES USEFUL AS 5-HT-2C RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267544-A1 | Use of LP-PLA2 Inhibitors in the Treatment and Prevention of Eye Diseases | PLA2G4A, PLA2G1B, PLA2G4B | HTR2C 4603/4885HTR2B 3214/4885HTR2A 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.